Cd80 extracellular domain polypeptides and their use in cancer treatment
AssigneeFive Prime Therapeutics, Inc.
InventorsThomas BRENNAN, David BELLOVIN, David BUSHA, Barbara SENNINO
Life of this patent
Estimating the term…
Abstract
This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
Claims45
A method of treating cancer in a subject comprising administering to the subject an effective amount of a composition comprising (i) CD80 extracellular domain (ECD) fusion molecules comprising the amino acid sequence of SEQ ID NO:20 and (ii) at least one pharmaceutically acceptable carrier, wherein the CD80 ECD fusion molecules comprise at least 15 moles of sialic acid (SA) per mole of CD80 ECD fusion protein.
A method of treating cancer in a subject comprising administering to the subject an effective amount of a composition comprising (i) CD80 ECD fusion molecules comprising the amino acid sequence of SEQ ID NO:20, and (ii) at least one pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.